Difference analyses showed that 7 of 10 CRGs were dys-regulated in tumor samples compared with those in normal samples, among which LIPT1, PDHA1, GLS and CDKN2A were up-regulated, and FDX1, DLD and MTF1 were down-regulated (Figure 1A). Here, CDKN2A is linked to neoplasm.